Bristol-myers Squibb Stock News

Bristol Myers Squibb said Wednesday it has entered a $5 billion accelerated share buyback program with Morgan Stanley, Barclays Bank, Citibank and JP Morgan. The deal is part of the drug company''s $15 billion share buyback program and it will have about $10.2 billion remaining in the authorization once the accelerated deal closes. Shares were up 0.7% premarket and have gained 10% in the last 12 months, while the S&P 500 has gained 15.5%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Bristol Myers Squibb (BMY) entered into accelerated share repurchase transactions to repurchase $5B of its stock.Under the agreements, the ASR transactions will be completed under…

REHOVOT, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced financial results for the year and the six months ended December 31, 2021. "We achieved significant progress in the advancement of our promising oncology pipeline during this year with notable data releases in both of our lead candidates," said Gil Efron, President and Chief Financial Officer of Purple Biotech. "For NT219, we are currently treating patients in the fourth dose cohort monotherapy arm of the ongoing Phase 1/2 clinical trial and have initiated the first dose level in the combination arm of the study together with cetuximab for patients with squamous cell carcinoma of head and neck (SCCHN). For CM24, we are about to complete dose escalation of the phase 1b/2 of the study and will soon initiate the expansion arms of the study in non-small-cell lung cancer (NSCLC) and pancreatic cancer.

WASHINGTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Non-Alcoholic Steatohepatitis (NASH) Market finds that growing demand for ideal NASH therapeutics is expediting market growth. Primarily driven by increasing pharmaceutical Research and Development (R&D) expenditure, the total global Non-Alcoholic Steatohepatitis (NASH) Market is estimated to reach USD 21,879 Million by 2028, up from USD 1,569 Million in 2021, at a Compound Annual Growth Rate (CAGR) of 60.4%. Furthermore, the escalating obese population across the globe is also anticipated to augment the growth of the Global Non-Alcoholic Steatohepatitis (NASH) Market, states Vantage Market Research, in a report, titled " Non Alcoholic Steatohepatitis (NASH) Market by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib), by Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)" .

Bristol Myers Squibb BMY, -0.45% said Wednesday it has entered a $5 billion accelerated share buyback program with Morgan Stanley, Barclays Bank, Citibank and JP Morgan. The deal is part of the drug c

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century T

NEW YORK , Feb. 8, 2022 /PRNewswire/ -- Sickle Cell Disease Treatment Market Facts at a Glance- Total Pages: 120 Companies: 10+ – Including Addmedica SAS, Bristol-Myers Squibb Co., Chiesi Pharmaceuticals BV, CRISPR Therapeutics AG, Emmaus Life Sciences Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Medunik USA , Novartis AG, and Pfizer Inc. among others. Coverage: Key drivers, trends, and challenges; Product insights & news; Value chain analysis; Parent market analysis; Vendor landscape; COVID impact & recovery analysis Segments: Indication (sickle cell anemia and others) Geographies: APAC ( China and India ), Europe ( Germany and UK), North America (US), South America , and MEA Didn''t Find What You Were Looking For? Customize Report- Don''t miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

NEW YORK , Feb. 8, 2022 /PRNewswire/ -- Sickle Cell Disease Treatment Market Facts at a Glance- Total Pages: 120 Companies: 10+ – Including Addmedica SAS, Bristol-Myers Squibb Co., Chiesi Pharmaceuticals BV, CRISPR Therapeutics AG, Emmaus Life Sciences Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Medunik USA , Novartis AG, and Pfizer Inc. among others. Coverage: Key drivers, trends, and challenges; Product insights & news; Value chain analysis; Parent market analysis; Vendor landscape; COVID impact & recovery analysis Segments: Indication (sickle cell anemia and others) Geographies: APAC ( China and India ), Europe ( Germany and UK), North America (US), South America , and MEA Didn''t Find What You Were Looking For? Customize Report- Don''t miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

Should investors be putting these pharmaceutical stocks on their watchlists?

Bristol Myers Squibb (BMY) awarded ~$7.97M in new health equity grants to 24 U.S

Bristol Myers Squibb (BMY) awarded ~$7.97M in new health equity grants to 24 U.S

Their dividends will be trickling into your account quarter after quarter.

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb . Looking at options history for Bristol-Myers Squibb (NYSE: BMY ) we detected 17 strange trades. If we consider the specifics of each trade, it is accurate to state that 64% of the investors opened trades with bullish expectations and 35% with bearish. From the overall spotted trades, 4 are puts, for a total amount of $1,398,225 and 13, calls, for a total amount of $617,654. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price … Full story available on Benzinga.com

Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.